Adoptive immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) is effective for the prophylaxis and treatment of EBV-induced lymphoma in hematopoietic stem cell recipients. However, in EBV-positive Hodgkin's disease (HD) the efficacy of adoptively transferred EBV-specific CTL may be limited by tumor-derived immunosuppressive factors, such as T-cell growth factor (TGF) b, interleukin (IL)13 and the chemokine TARC. Local delivery of IL12 to tumor sites by tumor-specific CTL could provide direct antitumor effects and overcome the CTL-inhibitory effects of the Th2 tumor environment while avoiding the systemic toxicity of recombinant IL12. EBV-specific CTL transduced with a retrovirus vector expressing the p40 and p35 subunits of IL12 as a single molecule (Flexi-IL12), produced IL12 following antigenic stimulation. This resulted in an elevated production of Th1 cytokines, including interferon g and tumor necrosis factor a, and a reduction in the Th2 cytokines IL4 and IL5. Flexi-IL12-transduced CTL resisted the antiproliferative and anticytotoxic effects of exogenous TGFb, likely by antagonizing the TGFb-induced downregulation of the Th1 transcriptional factor T-bet. In addition, Flexi-IL12-transduced CTL demonstrated a proliferative advantage in the presence of inhibitory supernatants from HD-derived cell lines. Tumor-specific, Flexi-IL12-transduced EBV-specific CTL should have a functional advantage over unmodified CTL, particularly in the presence of the adverse Th2 cytokine environment produced by Hodgkin tumor cells.
A doptive T-cell immunotherapy with human cytomegalovirus (CMV)-or Epstein-Barr virus (EBV)-specific, cytotoxic T cells (CTL) has been effective for the treatment of CMV-induced diseases and EBVassociated tumors in immunosuppressed patients. 1, 2 It was hoped that tumor-specific CTL could be of equal value for the treatment of many other human cancers. 3 However, immunogenic tumors that occur in immunocompetent individuals develop immune evasion strategies that impede tumor-specific cellular immunity. These evasion strategies have been shown to act at every step of T-cell induction and function, from the activation and maturation of professional antigen-presenting cells, to Tcell recruitment, activation and effector function. 4, 5 CD4 þ helper T (Th) cells and CD8 þ cytotoxic T cells (Tc) can be subdivided by the cytokines they secrete. Th1/ Tc1 cells secrete interferon (IFN) g and tumor necrosis factor (TNF) a, while Th2/Tc2 cells secrete interleukin (IL)4 and IL5. The differentiation of CD4 þ and CD8 þ cells to the Th1/Tc1 phenotype is favored in the presence of IFNg and IL12, while IL4 biases them towards the development of Th2/Tc2 cells. 6 Th1/Tc1 cells support cellmediated immune responses against viruses and tumors, while Th2 cells promote the development of humoral immune responses. The role of Tc2 cells is as yet unclear. 7 IL12 is among the most effective cytokines for stimulating antitumor immunity. 8, 9 It enhances the proliferation and lytic activity of Th1/Tc1 T cells and natural killer cells, in part by inducing the expression of cytokines, such as IFNg. 10 The in vivo antitumor activity of IL12 is also mediated by induction of IFNg and by inhibition of angiogenesis. 11 However, systemic administration of recombinant IL12 (rIL12) in cancer clinical trials led to severe, toxicity precluding its use at effective doses.
The malignant Hodgkin and Reed-Sternberg (H-RS) cells from up to 40% of patients with Hodgkin's disease (HD) carry the EBV genome and express EBV-encoded antigens. 13 They should thus be susceptible to EBVspecific CTL. We showed that gene-marked EBV-specific CTL infused into patients with EBV þ ve HD, expanded and survived for up to 9 months, homed to tumor sites and reduced EB viral load.
14 However, only partial responses of bulky tumors were observed. This limited efficacy may be due to the secretion by H-RS cells of immunosuppressive cytokines such as transforming growth factor b (TGFb), the Th2 cytokine IL13 and the Th2 attracting chemokine TARC by HD tumors. [15] [16] [17] We reasoned that local delivery of IL12 to Hodgkin tumors by EBV-specific CTL could improve the antitumor activity of the infused CTL in at least three separate ways. First, CTL could deliver the potent antitumor activity of IL12 to tumor sites, without inducing the systemic toxicity associated with this cytokine. 18 Second, IL12 could render CTL resistant to the inhibitory effects of the Th2 cytokine environment and third, by antagonizing the Th2 environment, IL12 might reduce the paracrine activity of the cytokine environment on the Hodgkin tumor cell growth. Our results show that functional IL12 can be produced by EBV-specific CTL when they encounter their target antigen, that the transduced CTL have enhanced Th1/ Tc1 activity and that transgenic IL12 counteracts the inhibitory effects of exogenous TGFb and of supernatants derived from Hodgkin cell lines.
Material and methods

Human donors
Donors HH and CB were two healthy volunteers, who donated blood with informed consent in a protocol approved by the Baylor College of Medicine Institutional Review Board. Two CTL lines were initiated from HH, 3 months apart.
Cell lines
The ecotropic packaging cell line Phoenix-eco was provided by Gary P Nolan, (Stanford, CA). 42 PG-13 (obtained from the American Type Culture Collection (ATCC)) is an amphotropic retrovirus packaging cell line and produces virus pseudotyped with the gibbon-ape leukemia virus (GALV). HSB-2 (ATCC cell line: CCL-120.1) is a T-cell lymphoma, which is sensitive to lymphokine-activated killer (LAK) cells and was used as a target in cytotoxicity assays. The HD-derived cell lines L1236 and HDLM2 were kindly provided by V Diehl (Cologne, Germany) and H Drexler (Braunschweig, Germany). 19, 20 EBV-transformed lymphoblastoid cell lines (LCL) were prepared as previously described. 14 
Flexi-IL12 plasmid
Flexi-IL12, first described by Anderson et al 21 consists of the p35 and p40 subunits of IL12 connected by a flexible linker. The linker sequence enables both subunits to fold in their natural three-dimensional structure and the single polypeptide has the biological activity of human IL12 (p70). This construction eliminates the possibility of uncoordinated expression of the two IL12 subunit cDNAs after transduction. The Flexi-IL12 cDNA was cloned into the BamHI and NcoI sites of the retroviral vector SFG (provided by RC Mulligan, Cambridge, MA). 22 
Production of recombinant retrovirus
The recombinant retrovirus was produced as described previously. 23, 24 Briefly, supernatants from the transiently transfected, ecotropic packaging cell line, Phoenix-eco, were used in two rounds of transduction of the packaging cell line PG13 in the presence of polybrene (8 mg/ml) for 48 hours at 321C. Viral supernatants were harvested from the resulting bulk producer lines by adding 20% IMDM to the PG-13 cells and incubated at 321C for 24 hours. The supernatant was harvested, filtered using a 0.45 mm filter and used directly to transduce CTLs.
Generation and transduction of EBV-specific CTL cultures
EBV-specific CTL were activated by stimulation of PBMC with the autologous EBV-transformed LCL in complete medium (RPMI 1640 (Hyclone), supplemented with 45% EHAA (Clicks, GIBCO-BRL, Gaithersburg, MD), 10% Fetal calf serum (Hyclone) and 200 mM Lglutamine) (CM) and expanded by weekly LCL stimulation and twice weekly IL2 from day 14, as previously described. 43, 24, 14 Prior to retrovirus transduction, CTL were activated on OKT-3 (1 mg/ml; Ortho Pharmaceuticals, Raritan, NJ) and anti-CD28 antibody (1 mg/ml; Pharmingen, San Diego, CA)-coated plates 1 day after the third LCL stimulation. After 24 hours, the CTL were transferred to new noncoated 24-well plates (Costar) at 1 Â 10 6 cells/ml and cultured for another 24 hours in CM supplemented with rIL2 (100 IU/ml) before transduction on non-tissue-culture-treated plates (Becton Dickinson, San Jose, CA), coated with recombinant fibronectin fragment (FN CH-296) (Retronectint, Takara Shuzo, Otsu, Japan) at a concentration of 4 mg/ml, and incubated with equal volumes of freshly generated viral supernatant for 36 hours. 23, 24 As a control, CTL were also transduced with a SFG retrovirus vector encoding the enhanced green fluorescent protein (eGFP). In some experiments, transduced and nontransduced CTL cells were cultured in the presence of recombinant TGFb or IL12 at the concentrations indicated (R&D Systems, Minneapolis, MN).
Flow cytometry
Cells were immunophenotyped with fluorescein (FITC)-or phycoerythrin (PE)-conjugated monoclonal antibodies (Becton Dickinson) directed against CD3, CD4, CD8, and CD56 surface proteins as well as against the T-cell receptor (TCR) ab-and gd-chain. The intracellular IL12 or intracellular perforin assays were performed by fixing the CTL in 4% paraformaldehyde (Sigma, St Louis, MO) for 20 minutes. The cells were then washed in permeabilizing buffer (1 Â PBS (GibcoBRL, Gaithersburg, MD) þ 0.1% saponin (Sigma) þ 1% FCS (Hyclone, Logan, UT)). CTL were incubated in 3 ml permeabilizing buffer with 5% human AB serum (C-six Diagnostics Inc, Germantown, WI) for 10 minutes at room temperature (RT), then resuspended in 100 ml permeabilizing buffer. To each sample, 10 ml of either PE-labeled anti-IL12 (p70) antibody (Pharmingen, San Diego, CA) or PE-labeled antiperforin antibody (Becton Dickinson) were added and incubated for 30 minutes at RT. Samples stained with a PE-IgG1 isotype control (Pharmingen) were run in parallel. CTL were washed again with permeabilizing buffer and resuspended in 1 Â PBS þ 1% FCS and analyzed immediately. For each sample, 10,000 cells were analyzed using a FACSCalibur flow cytometer with the Cell Quest Software (Becton Dickinson).
Measurement of cytokine production by ELISA and cytokine cytometric bead array IL12, IFNg, IL13 and TGFb in cell culture supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Quantikine immunoassay, R&D systems). The production of IL4, IL5, IL10 and TNFa in CTL culture supernatants was measured using the Human Th1/Th2 cytokine cytometric Bead Array (BD Pharmingen, San Diego, CA).
Cytotoxicity assays
Standard
51
Cr release assays were used to test the cytotoxic specificity of transduced and nontransduced CTL as described elsewhere in detail. 25 Target cells included autologous LCL, HLA class I and II mismatched LCL, and the LAK-cell-sensitive cell line, HSB-2. The mean percentage of specific lysis of triplicate wells was calculated as follows: ((test counts-spontaneous counts)/(maximum counts-spontaneous counts)) Â 100%.
Proliferation assays
Transduced and nontransduced CTL were incubated in triplicate at 5 Â 10 4 cells/well with irradiated autologous EBV-LCLs at a 4:1 stimulator to responder ratio. After 72 hours, wells were pulsed with 1 mCi/well of [ 
Real-time quantitative polymerase chain reaction (RQ-PCR)
RQ-PCR with the 5 0 nuclease technology (TaqMan technology; PE Applied Biosystems, Foster City, CA) was used to determine the transduction efficiency of Flexi-IL12-transduced cells in DNA samples of CTL cultures and to compare gene expression levels in transduced and nontransduced cells. Primers and probes were designed using the Primer Express Software (PE Applied Biosystems) to distinguish between endogenous p35 and p40 as well as Flexi-IL12 sequences in DNA and cDNA preparations. To detect DNA and cDNA sequences of Flexi-IL12, we used a forward primer (Flexi-IL12 forward) binding to the 3 0 end of p40 and a reverse primer (p35 common reverse) binding to exon two of p35, whereas the probes (p35 common) annealed to exon two of p35. The specificity for human p35 transcripts was achieved by replacing the forward primer with an oligonucleotide (human p35 forward) spanning the junction of exons 1 and 2, which is deleted in Flexi-IL12. Human p40 transcription was specifically detected in cDNA preparations by using a forward primer (human p40 forward) which binds to exon 1 in human p40 and which is deleted in Flexi-IL12, a reverse primer (p40 reverse) annealing to exon 2 of p40 and a probe (human p40 probe) spanning the junction of exons 1 and 2 in the human p40 gene. The sequences are as follows:
ACGGT-CATCTGCCGCAAA, Human p35 forward primer GTCCAGCGCG-CAGCC, p35 common reverse primer TTTGGGAGTGGT-GAAGGCAT, p35 common probe FAM-TGGCCACTCCAGACC-CAGGAATGTT-TAMRA, Human p40 forward primer ATCTGTTTCAGGGC-CATTGG, p40 reverse primer GAGATGCCAGAAAAAC-CAGGG, Human p40 probe FAM-TGCCAAGAGCAA-GATGTGTCACCAG-TAMRA.
DNA was extracted from cells using the QIAamp Blood Mini Kit (Qiagen, Valencia, CA). In total, 500 ng of DNA solution was analyzed in duplicate for each sample. For quantification of Flexi-IL12 in samples, serial 1:4-fold dilutions of the plasmid pSFG-Flexi-IL12 with known copy numbers (32-131,072 copies/sample) were used as standard. To increase precision, the input level of cellular DNA in samples was normalized using primers and a probe specific for C-reactive protein (CRP) DNA, as described elsewhere. 26 A correlation coefficient of 40.99 was found over at least five orders of magnitude after amplification of the Flexi-IL12 and CRP standard. The normalized Flexi-IL12 levels in samples were expressed as Flexi-IL12 copy numbers per microgram of amplifiable genomic DNA.
For cytokine gene expression analysis, total RNA was extracted using the RNeasy Mini Kit (Qiagen). RNA was eluted in 40 ml RNAse-free water and stored at À801C until use. After DNAse I digestion (Gibco Invitrogen Corporation, Carlsbad, CA) RNA was reverse transcribed to complementary DNA (cDNA) using random hexamers and the Supercript II reverse transcriptase (SuperScript First-Strand Synthesis System for RT-PCR, Gibco). Expression of the Flexi-IL12-, human p35-and human p40 genes was analyzed using the primer and probe combinations described above. For quantification of T-bet expression, cDNA-specific primers and probe were designed using the T-bet mRNA sequence form the GenBank database, accession number AF241243, and the Primer Express Software (PE Applied Biosystems).
The sequences of primers and the probe specific for Tbet cDNA are (5 0 3 0 ): T-bet forward (exon 4) AGAAACC-CAGTTCATTGCCG, T-bet reverse (exon 5) GGAATCCTTTGGCAAAGGG, T-bet probe (spanning the exons 4-5 junction) FAM-TGCCTACCA-GAATGCCGAGATTACTCAGCT-TAMRA. The primers and probe of the predeveloped TaqMan Assay Reagents Human IL4 and TGFb (PE Applied Biosystems) were used to analyze the expression of human IL4 in transduced or nontransduced CTL or of TGFb in HDderived cell lines. As a positive control and calibrator for relative quantification, samples were analyzed with the TaqMan Ribosomal RNA Control Reagents (PE Applied Biosystems) according to the manufacturer's protocol. RNA without reverse transcriptase was run in parallel for each sample. All samples were analyzed in duplicate. For relative quantification, the expression of genes in samples was normalized by comparison with the rRNA amount using the DDC T method. 27 The PCR mixture for DNA or cDNA amplification consisted of 2 Â TaqMan Universal Master Mix (PE Applied Biosystems) adjusted to a volume of 50 ml with primers (300 nM concentration of each), 200 nM of the probe, respectively, template and nuclease-free water (Promega, Madison, WI). The PCR amplification used the ABI PRISM 7700 Sequence Detection System (SDS) (PE Applied Biosystems). We used settings of 2 minutes at 501C (inactivation of possible carryover contamination by uracil N 0 -glycosylase (UNG)), 10 minutes at 951C (UNG inactivation and activation of the DNA polymerase) and 40 two-step cycles of 15 seconds at 951C and 60 seconds at 601C. Real-time fluorescence was measured, and the threshold (C T ) cycles of amplifications, where the plots crossed a defined baseline, were determined for each sample.
Statistical analysis
For comparison of proliferation of CTL, the MannWhitney U-test was used. A P-value o.05 was regarded to be statistically significant. Calculations were performed using the software SPSS 8.0 for Windows (SPSS Inc., Richmond, CA).
Results
Flexi-IL12 is stably integrated and expressed
Three EBV-specific CTL lines (CB, HH1 and HH2) were transduced with the retroviral vector SFG-Flexi-IL12 or SFG-eGFP. Between 8 and 24% of CTL expressed eGFP after transduction with SFG-eGFP. As shown in Figure  1a and b, endogenous IL12 was never detected by intracellular cytokine staining or ELISA in nontransduced or eGFP-transduced CTL. In contrast, after transduction with SFG-Flexi-IL12, IL12 could be detected in 9, 30 and 60% of the three CTL populations, in quantities proportional to the percentage of IL12-producing cells (Fig 1a and b) .
Flexi-IL12 DNA was detected using intracellular cytokine and ELISA assays only in IL12-transduced cells. By comparing the integrant number detected by PCR with the frequency of cells expressing IL12 in the intracellular cytokine assay, we calculated that the average number of integrants in these cell lines ranged from 3.9 and 7.2 per cell. ELISA assays (Fig 2) and intracellular cytokine assays (not shown) demonstrated that the percentage of IL12-positive cells and their cytokine secretion remained stable over at least 3 weeks.
Transgenic IL12 modulates CTL proliferation
The two transduced CTL lines with the higher percentage of IL12-expressing cells (30 and 60%) showed decreased proliferation as measured by [ 3 H] thymidine uptake when compared to their nontransduced and eGFPtransduced controls. However, when transduced CTL were diluted in nontransduced CTL, so that 5, 1 and 0.2% of cells expressed intracellular IL12, their proliferation was significantly increased compared with nontransduced and eGFP-transduced CTL controls (Figure 3 ). This suggests that while small amounts of IL12 promote CTL proliferation, excessive IL12 inhibits their expansion.
Effects of Flexi-IL12 on the phenotype and cytotoxic function of CTL
Compared with nontransduced and eGFP-transduced CTL, the percentage of CD8/CD56-double-positive LAK cells was increased in Flexi-IL12-transduced CTL, likely because IL12 stimulates both T and LAK cells. 25 However, the overall CD4/CD8 ratio and TCR ab expression were unchanged. The transduced CTL also retained their cytotoxic specificity for autologous EBVinfected target cells, and there was no elevated killing of the LAK-sensitive target HSB-2, or of HLA-mismatched allogeneic LCLs. Table 1 compares the cytotoxic specificity of untransduced and 30% Flexi-IL12-transduced CTL. EGFP-transduced and 5%-Flexi-IL12-transduced CTL produced similar results (not shown). A proportion of both the HH and CB cell lines reacted with LMP2, one of the EBV proteins expressed in H-RS cells. In HH-CTL, 2.85 and 0.8% of the T cells reacted with HLA-A2 tetramers carrying the LMP2 peptides CLGGLLTMV and FLYALALL, while 0.4% of CB CTL produced g-IFN in response to FLYALALL in Elispot assays (data not shown). 28 Flexi-IL12 increases the expression of Tc1/Th1 cytokines and decreases the production of Tc2/Th2 cytokines The induction of IFNg production from T cells is a hallmark of IL12 activity. Table 2 shows that IFNg expression by CTL is greatly increased following Flexi-IL12 transduction. Production of TNFa, IL10 and IL2 Targeting IL12 to HD by EBV-specific CTL H-J Wagner et al was similarly increased by transgenic IL12 expression ( Table 2) . Production of IL5, a Tc2/Th2 cytokine, was decreased in Flexi-IL12-transduced CTL compared with controls. Similar effects were observed for IL4 gene expression by real-time PCR analysis (DDC T method).
27
Although IL4 protein expression was below the level of detection in the cytokine cytometric bead array, the expression of IL-4 mRNA fell to less than 40% by 1 day after transduction and to less than 5% by day 7, even though only 30% of the cells were transduced (not shown).
Safety issues with the clinical use of IL12-transduced CTL
One concern about forced expression of IL12 in CTL is the possibility of uncontrolled autocrine growth stimulation by IL12. The dependence of transgene production on antigen stimulation offers some reassurance, but to further exclude this possibility, we analyzed the growth of Flexi-IL12-transduced cells in the presence and absence of exogenous growth stimuli. Flexi-IL12-transduced CTL failed to proliferate and became nonviable after 3 weeks Targeting IL12 to HD by EBV-specific CTL H-J Wagner et al in the absence of rIL2 and LCL stimulation, whereas with appropriate growth stimuli transduced and nontransduced CTL showed typical proliferation during this period (Figure 4a) . A second concern is that high levels of IL12 may not only inhibit T-cell proliferation, but also induce systemic toxicity. Retrovirus transgene expression has been shown to be dependent on the activation status of the transduced T cell. 29 It would be desirable if transgenic IL12 was produced predominantly following T-cell encounter with its specific target antigen. Expression of Flexi-IL12 was therefore analyzed before and immediately after exposure to EBV-expressing target cells. We found that the expression of Flexi-IL12 was increased 25-fold after antigenic restimulation so that optimal expression requires antigenic stimulation (Fig 4b) .
A third concern was that IL12 might stimulate the proliferation of H-RS cells when produced at tumor sites. However, culture of the HD-derived cell lines L1236 and HDLM2 in the absence and presence of recombinant IL12 at two different concentrations (5 and 10 ng/ml) over a period of 1 week produced no difference in growth rate or cytokine production. Recombinant IL12 did not induce IFNg expression in culture supernatants nor did it affect their characteristic production of IL13 and TGFb mRNA and protein (not shown). These results suggested that HD-cell lines were unresponsive to IL12.
Flexi-IL12-transduced CTL resist the antiproliferative and anticytotoxic effects of TGFb
One of the major immune evasion strategies used by Hodgkin tumors may be their production of TGFb, which has antiproliferative effects on CTLs and inhibits their cytotoxic function and cytokine production. 4, 24 We therefore determined whether these inhibitory effects could be overcome by IL12 expression. Transduced and nontransduced CTL were cultured in the presence (1 and 2.5 ng/ml) or absence of TGFb. Figure 5a shows [ 3 H] thymidine uptake by Flexi-IL12-transduced or control CTL, 72 hours after the fifth stimulation with the autologous LCL. While both concentrations of TGFb had an antiproliferative effect on transduced and nontransduced CTL, the inhibition of thymidine uptake by Flexi-IL12-transduced CTL was significantly lower than of GFP-transduced or nontransduced CTL (Po.05).
Further, while TGFb reduced IFNg production by Flexi-IL12-transduced cells, the overall level of IFNg produced in the presence of TGFb remained higher than by control CTL cultured in the absence of TGFb (Fig 5b) . Similarly, the TGFb mediated reduction in intracellular perforin 24 was less evident in the Flexi-IL12-transduced compared with control CTL (Fig 5c) .
Transgenic IL12 antagonizes TGFb-mediated inhibition of T-bet expression in CTL
To examine the molecular mechanisms underlying the resistance of Flexi-IL12-transduced CTL to TGFb, we measured the expression of the Th1/Tc1 differentiation factor T-bet, which is controlled antagonistically by IL12 and TGFb. 30 When control CTL were cultured in the presence of exogenous TGFb (1 and 2.5 ng/ml for 72 hours), the expression of T-bet mRNA markedly decreased. In contrast, Flexi-IL12-transduced CTL showed a higher expression of T-bet mRNA when The table shows the percent specific lysis of 51 Cr-labeled autologous LCL (auto), HLA-mismatched LCL (allo) and the LAK cell target, HSB-2 by EBV-specific CTL from HH-2 which were nontransduced (NT) or transduced with flexi-IL12 with 30% of the cells expressing IL12. 
Flexi-IL12-transduced CTL resist the antiproliferative effects of HD-derived cell lines
To examine the net influence of the inhibitory cytokines produced by H-RS cells on CTL growth, we cultured Flexi-IL12-transduced and control CTL with supernatants from the HD-derived cell lines L1236 and HDLM2. Flexi-IL12-transduced CTL continued to proliferate in the presence of the supernatant of L1236 and HDLM2 compared with the control CTL, indicating resistance towards the inhibitory effects produced by H-RS cells ( Figure 7 ).
Discussion
We have begun to investigate the feasibility of targeting the potent antitumor activity of IL12 to tumor cells using tumor-specific CTL and we have shown that CTL are able to express and secrete IL12 without negative effects. This strategy requires that CTL express both chains of the IL12 heterodimer, without toxicity to the CTL, without altering the antitumor activity of the CTL and without causing uncontrolled CTL proliferation. EBV-specific CTL transduced with a retrovirus encoding a fusion protein composed of the p35 and the p40 chains of human IL12 attached by a flexible linker expressed biologically active IL12 following exposure to antigen. The transduced CTLs demonstrated increased Th1 and decreased Th2 cytokine production. The only phenotypic difference detected between Flexi-IL12 and mock-transduced CTL was a small increase in the expression of the LAK-cell marker, CD56 on CD3 þ /CD8 þ T cells. This however, was not accompanied by increased LAK activity. Flexi-IL12-transduced CTL retained their cytotoxic specificity and their dependence on antigenic stimulation and IL2 for sustained proliferation. The transduced CTLs resisted the antiproliferative and anticytotoxic effects of exogenous TGFb, a characteristic that may be mediated through the Th1 transcription factor T-bet.
While production of high concentrations of IL12 in CTL transduced at high levels appeared to limit the growth of the culture as a whole, there was no evidence that expression of IL12 was directly toxic to the transduced cells, since their dilution in nontransduced CTL allowed the stable maintenance of the transduced population. Furthermore, CTL with a high intracellular IL12 production were not preferentially lost. Importantly, while biologically active amounts of IL12 were produced following CTL activation in response to the target antigen, levels were greatly reduced with time in the absence of repeated antigenic stimulation. That expression of transgenic IL12 was produced predominantly after T-cell stimulation by their target antigen reiterates the finding that transgene expression in retrovirally trans- Supernatants were harvested 24, 48 and 72 hours after the sixth stimulation of transduced and nontransduced (NT) CTL HH with the autologous LCL and tested for the production of the indicated cytokines by ELISA or cytokine cytometric bead array. In order to avoid an overlap with exogenously added rIL2 in CTL cultures, IL2 was only analyzed 72 hours after stimulation. Median values of cytokines are indicated in pg/ml. The other two CTL lines gave similar results for their cytokine production.
duced T cells is regulated by their activation state. Thus maintenance of transduced T cells in IL2 alone resulted in transgene silencing, while reactivation with immobilized anti-CD3/anti-CD28 antibodies upregulated transgene expression. 29 In vivo mouse models of adoptive immunotherapy for tumors, have shown that tumor-specific Tc1 and Tc2 cells differ in their functional ability to provide antitumor immunity. Tc1 cells were able to significantly delay tumor growth, whereas Tc2 cells had only limited effect. Furthermore, secretion of high amounts of IFNg by Tc1 cells appeared to be a critical antitumor effector mechanism. 31 Compared with eGFP-and nontransduced CTL, Flexi-IL12-transduced CTL produced very high levels of IFNg and other Th1/Tc1 cytokines, which should enhance antitumor activity even in the presence of Th2 cytokines produced in the tumor microenvironment. Of note, we also detected increased production of IL10 after Flexi-IL12 transduction. While this cytokine has Th2/Tc2 effects, these are directed against professional antigenpresenting cells. 6 IL10 does not affect the ability of B cells to present antigens and its direct effects on CTL are positive and IL10 increases virus-specific cytotoxicity. 32, 33 Recombinant IL12 has been delivered systemically in clinical trials for renal, colon and ovarian cancers and for malignant melanoma. 34 The regimens were highly toxic with 10-15% mortality in patients with advanced stage renal cell carcinoma. 12 Several attempts have been made to avoid systemic toxicity by local delivery. Regression of murine tumors was observed in the majority of mice receiving intratumoral injection with an adenovirus vector expressing IL12. The mice were also immune to tumor rechallenge. 18 In a clinical study, autologous dermal fibroblasts were transduced with a retrovirus encoding both subunits of IL12 and injected peritumorally. Treatment-related adverse events were local and limited, and antitumor responses were seen, one of which was in a distal metastasis. 35 Delivery of IL12 by tumor-specific CTL extends this concept and should allow targeting even of disseminated disease and micrometastasis.
We chose to make use of the ''Flexi-IL12'' p70 fusion construct because of concerns about efficient assembly of IL12 and unequal production of each chain when a more conventional bicistronic approach is adopted. 36, 21 Our data confirm that this approach leads to production of high levels of biologically functional IL12 with little evident impairment of T-cell behavior.
EBV-positive HD was the target of our approach, because the Hodgkin-Reed Sternberg (HRS) cells in this disease not only express well-defined viral antigens, but also secrete chemokines and cytokines that create a Th2 environment that is hostile to Th1 CTLs. 37, 17, 4 IL12-secreting EBV-specific CTL should have improved antitumor efficacy in several ways. IL12 will antagonize tumor-infiltrating Th2 cells that exert both paracrine and protective effects on the tumor cells. IL12 has direct antitumor activity by inducing IFNg and inhibiting angiogenesis and IL12 should protect the transduced CTLs from the Th2 environment, increasing their ability to persist, proliferate and function within the tumor environment. 38 Indeed we demonstrated that transgenic expression of IL12 in CTL not only increases Th1 and decreases Th2 cytokine production but also creates resistance to the antiproliferative and anticytotoxic effects of TGFb, which is secreted by HD tumors. 4 TGFb and IL12 act through different specific signaling pathways, Targeting IL12 to HD by EBV-specific CTL H-J Wagner et al but have antagonistic effects on the expression of T-bet, a transcription factor crucial for Th1 development and differentiation. 39, 30 Thus, IL12 activation of T-bet may explain the resistance of Flexi-IL12-transduced CTL to TGFb.
We have previously demonstrated that gene-marked, EBV-specific CTL can be generated from and safely infused into patients with EBV-positive HD. The infused CTL persisted for up to 9 months, and gene-marked cells could be demonstrated in tumor tissues including a malignant pleural effusion and a mediastinal tumor. CTL infusions produced antiviral effects and mixed tumor responses, 14 (and manuscript in preparation). Thus our proposed approach is clinically feasible. CTL could directly deliver IL12 with its potent Th1/Tc1 immunoregulatory and antitumor functions to the tumor sites, thereby increasing the desired effects locally, while minimizing the potential adverse systemic effects.
If IL12 producing CTL prove effective in the context of HD, they may also be of value in the adoptive immunotherapy of EBV-associated nasopharyngeal carcinoma as well as for many other immunogenic tumors that use TGFb as an immune evasion strategy. 10, 40 IL12-transduced CTL may also be of interest for other infections, such as HIV, in which the progressive loss of Th1 cytokine production is thought to play a major role in the development of the immunodeficiency syndrome. 41 
